The randomized controlled trial of Smecta efficacy in abdominal purpura gut barrier dysfunction

The randomized controlled trial of Montmorillonite efficacy in abdominal purpura gut barrier dysfunction

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16008658

Enrollment

Unknown

Registered

2016-06-16

Start date

2016-07-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Henoch-Schonlein purpur (HSP)

Interventions

control group :no

experimental group:oral Smecta

Eligibility

Sex/Gender

All

Age

3 Years to 17 Years

Inclusion criteria

Inclusion criteria: 1. Children with abdominal symptoms were diagnosed as HSP; 2. Aged <18 years; 3. The guardian agree with the specimen collection and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Children who used smecta or similar drugs within two weeks were excluded; 2. Children who suffered gastrointestinal bleeding or shock excluded; 3. Patient who do not want to participate in this study were excluded.

Design outcomes

Primary

Measure	Time frame
Diamine oxidase, D- lactic acid, endotoxin;	—

Countries

China

Contacts

Public ContactXiaolin Gao

West China Second Hospital, Sichuan University.

23132875@qq.com+86 13982036184

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026